Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
about
Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosisLiposomal packaging generates Wnt protein with in vivo biological activityTargeted delivery of amikacin into granuloma.Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.Versatility of aminoglycosides and prospects for their future.Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.Nanomedicine as an emerging approach against intracellular pathogensSuppression of premature termination codons as a therapeutic approach.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections.Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases.Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains.Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.Therapeutics based on stop codon readthrough.Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants.Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs.Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles.Nanoparticles: Emerging carriers for drug delivery.Laser interferometry analysis of ciprofloxacin and ampicillin diffusion from liposomal solutions to water phase.Liposome combined porous beta-TCP scaffold: preparation, characterization, and anti-biofilm activity.Tissue tolerance of diclofenac sodium encapsulated in liposomes after intramuscular administration.The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles.Development and optimization of solid lipid nanoparticles of amikacin by central composite design.Visualizing in vivo liposomal drug delivery in real-time.Calli Essential Oils Synergize with Lawsone against Multidrug Resistant Pathogens.Modulatory Effects of Breed, Feeding Status, and Diet on Adipogenic, Lipogenic, and Lipolytic Gene Expression in Growing Iberian and Duroc Pigs.Amikacin: Uses, Resistance, and Prospects for Inhibition.Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.
P2860
Q28475562-1E654F89-01C3-4EEB-B54E-7F24491D4D08Q33359570-42BFD411-BE3C-43DE-A611-CD5B37EA6432Q33652356-26227ED5-EBDE-40B0-A1B4-96F70D307040Q33797873-E76AEC97-E36F-4B17-BC8F-9F8F7C3145BCQ34166700-C086CA16-8B98-4FFE-B42E-97E1A4E6E9C6Q34423372-BE2050CF-4658-4BFA-B0B3-DFACD3A4424AQ35176271-B24F8C3D-F188-4E27-ACC5-472BE463C6A8Q35287888-E8B28392-F746-4C79-B996-16EBB6E01FD9Q35656908-1A5E4738-477A-43E7-8343-42CF9D9EC2D2Q36203719-8DF43E5F-A453-4731-A485-78532A88798BQ36607415-7B896556-EB3B-4747-A2D0-47BDF7DB9C2DQ36985919-E0BBB7C2-544B-49D9-B1D6-E91B2C9E8451Q37050322-09EB327B-2F0D-400D-978E-30CA542263F0Q37159968-1A771018-7117-4B69-9B0C-4D2693240322Q37263845-62EC6E55-B63E-41B4-A74F-14EA6403159AQ37638359-A59C6761-3BFC-4561-BDB3-299C40EE728EQ37790712-10EF4A27-3277-4758-AEA1-78328CF28BB1Q38072030-3C494ACD-97C5-40F1-9C68-16ECEB776407Q38406190-71C68BE1-C766-4043-AC21-4A1B68432F1EQ38938501-DE5433B1-679F-4170-A11A-7727C57C0F2CQ41948736-FCC37282-F86F-4DBC-B7B8-140191E68AFAQ42009342-3ABCAAA6-25B8-4869-B616-49C3E91C805CQ42142212-D48270DC-6192-45A3-B0D8-BD42C3B5B63FQ43080159-6D4DA8C5-2D2E-42B0-86AD-3E3D31198B1CQ44084005-89AEA33E-61EA-49C2-AB4D-5D7658AF5532Q44877819-03F53D4C-1E92-4807-8054-F42ABDEE6431Q45923988-24FA1D8E-5FF1-42C4-98AA-547B84B05537Q46925113-40E3FC75-1888-4823-841A-8C042E3C471FQ47562417-2FF306EF-8070-48A0-83A9-FBC69723D8D8Q49812805-41985128-74DA-457D-BBEA-6A29329CB719Q52744431-1530CFED-7D11-4D39-BBCB-A0EB27D8892AQ55497000-9E534FB7-3138-4490-BCD2-B70E03D8B50A
P2860
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@ast
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@en
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@nl
type
label
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@ast
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@en
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@nl
prefLabel
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@ast
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@en
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@nl
P2093
P356
P1476
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies.
@en
P2093
Bakker-Woudenberg I
Schiffelers R
P304
P356
10.1093/JAC/48.3.333
P407
P577
2001-09-01T00:00:00Z